ABSTRACT
Although there have been a few reports regarding fenofibrate-induced rhabdomyolysisin patients with hypothyroidism, there are no data in literature that this could occur in patients with subclinical hypothyroidism. We report a case of subclinical hypothyroidism and end-stage renal failure who presented with rhabdomyolysis while taking fenofibratefordys lipidemia. Two weeks after beginning fenofibrate,a54-year-oldmale patient with end-stage renal failure was admitted to our hospital with complaints of myalgia and muscle weakness. Laboratory tests revealed a creatine kinase of 51,858 U/l, thyroid stimulating hormone of 10.26 micro IU/ml, free T3 3.61 pg/ml, free T4 0.74 ng/dl. Fenofibrate was stopped and tiroxin dosage increased. Hemodialysis was performed four times. During follow-up, serum creatine kinase level decreased to 160 U/l at the end of one week. Physicians should be aware of potentially lethal adverse effects including rhabdomyolysis after fenofibrate therapy in patients with subclinical hypothyroidism and end-stage renal failure. They should carefully follow-up hepatic and muscle enzymes
ABSTRACT
Rhabdomyolysis is one of the causes of acute renal failure [ARF] and it can be Life-threatening in some cases. Hypocalcemia is prominent during the oliguric phase of renal failure and if the patient reaches the diuretic phase, hypercalcemia can develop. We report a 20-year-old male patient with rhabdomyolysis-induced ARF with bi-phasic calcium metabolism observed during the course of ARF